Recent Updates — AQB
AquaBounty Technologies converted all outstanding Series A (263,753 shares) and Series B (109,223 shares) Preferred Stock into an aggregate of 8,077,043 shares of Common Stock. The conversion was triggered by the SEC declaring the company's Form S-3 registration statement effective on October 23, 2026. Post-conversion, no preferred stock remains outstanding and total common shares increased to 13,291,953. AquaBounty Technologies develops genetically modified salmon for aquaculture.
AquaBounty Technologies entered into conversion agreements with holders of its Series A and Series B Convertible Preferred Stock, triggering the automatic conversion of all outstanding preferred shares into common equity upon the earlier of SEC declaration of effectiveness or October 30, 2026. The transaction results in the issuance of approximately 8.1 million new common shares, calculated based on liquidation values and accrued dividends waived through mid-October. The company has agreed to file a Form S-3 registration statement to facilitate the resale of these conversion shares. AquaBounty Technologies develops and markets genetically modified Atlantic salmon for aquaculture.
AquaBounty Technologies announced an expansion of its strategic review process for its Pioneer, Ohio property to include power infrastructure and energy development opportunities. While discussions with the aquaculture industry continue, the company is now evaluating transactions such as sales, joint developments, or leases with parties interested in the site's electrical substation capacity, electricity pricing, and water resources. AquaBounty operates in the aquaculture sector.
AquaBounty Technologies, Inc. announced that its Board of Directors determined not to implement the previously approved reverse stock split authority granted by stockholders-at-the-June 23, 2026, Annual Meeting. The authority to effect a reverse stock split between 1-for-5 and 1-for-20 ratio will expire on July 31, 2026, without being exercised. AquaBounty Technologies, Inc. operates in the aquaculture industry and develops genetically modified salmon.
On June 25, 2026, AquaBounty Technologies, Inc. completed a private placement, issuing 109,223 shares of Series B Convertible Preferred Stock for aggregate gross proceeds of $2,250,000. The Series B Preferred Stock has a liquidation value of $20.60 per share, an 18.0% annual dividend accruing quarterly, and is convertible into common stock at an initial price of $1.03 per share. Univest Securities, LLC served as the placement agent and received a fee of 7.0% of gross proceeds. Net proceeds are intended for working capital and general corporate purposes. The company operates in the aquaculture industry and produces genetically engineered salmon.
At its Annual Meeting on June 23, 2026, AquaBounty Technologies stockholders approved an amendment to the Certificate of Incorporation granting the Board discretion to execute a reverse stock split with a ratio between 1-for-5 and 1-for-20. The Board must determine the final ratio and timing, with the split to occur no later than July 31, 2026. Stockholders also elected directors Graydon Bensler, Braeden Lichti, Rick Sterling, and Sylvia A. Wulf, ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and approved executive compensation on an advisory basis. The company operates in the aquaculture industry and produces genetically engineered salmon.